1. Home
  2. DSP vs MDWD Comparison

DSP vs MDWD Comparison

Compare DSP & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$12.17

Market Cap

213.3M

Sector

Technology

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$14.20

Market Cap

212.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
MDWD
Founded
1999
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.3M
212.1M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DSP
MDWD
Price
$12.17
$14.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$17.81
$36.00
AVG Volume (30 Days)
297.1K
98.1K
Earning Date
05-11-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
N/A
EPS
N/A
N/A
Revenue
$344,201,000.00
N/A
Revenue This Year
$20.27
$48.92
Revenue Next Year
$16.88
$35.04
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$13.54
52 Week High
$15.18
$21.63

Technical Indicators

Market Signals
Indicator
DSP
MDWD
Relative Strength Index (RSI) 53.46 35.16
Support Level $10.86 N/A
Resistance Level $12.61 $18.49
Average True Range (ATR) 0.88 0.68
MACD 0.13 -0.19
Stochastic Oscillator 47.03 17.98

Price Performance

Historical Comparison
DSP
MDWD

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: